Table 3 Changes in outcome measures of patients with convergence insufficiency by treatment group
CISS score | Baseline | 6 weeks | 12 weeks | Total change |
VR group | 27.69 ± 8.50 | 22.63 ± 9.88 | 21.75 ± 9.13 | -5.94 ± 3.11 |
OBVAT group | 25.18 ± 9.40 | 18.82 ± 8.15 | 16.47 ± 8.02 | -8.71 ± 2.99 |
Effect size | group | group*time | time | |
 F value | 2.298 | 0.424 | 13.074 | |
 P value | 0.140 | 0.656 |  < 0.001 | |
NPC break (cm) | Baseline | 6 weeks | 12 weeks | Total change |
 VR group | 6.59 ± 3.63 | 5.06 ± 2.73 | 4.62 ± 2.38 | -1.97 ± 1.09 |
 OBVAT group | 6.00 ± 2.95 | 3.91 ± 1.99 | 3.82 ± 1.41 | -2.18 ± 0.80 |
Effect size | group | group*time | time | |
 F value | 1.084 | 0.478 | 13.290 | |
 P value | 0.306 | 0.624 |  < 0.001 | |
PFV blur or break at near (â–³) | Baseline | 6 weeks | 12 weeks | Total change |
 VR group | 22.63 ± 6.15 | 32.97 ± 7.98 | 34.47 ± 5.20 | 11.84 ± 2.01 |
 OBVAT group | 23.06 ± 5.18 | 34.68 ± 5.98 | 35.47 ± 4.64 | 12.41 ± 1.69 |
Effect size | group | group*time | time | |
 F value | 0.421 | 0.008 | 61.222 | |
 P value | 0.521 | 0.888 |  < 0.001 | |
Near horizontal phoria (â–³) | Baseline | 6 weeks | 12 weeks | Total change |
 VR group | -16.31 ± 3.99 | -13.94 ± 4.60 | -13.13 ± 5.15 | 3.19 ± 1.63 |
 OBVAT group | -15.35 ± 2.83 | -11.53 ± 5.62 | -9.94 ± 6.33 | 5.41 ± 1.68 |
Effect size | group | group*time | time | |
 F value | 2.261 | 1.067 | 16.482 | |
 P value | 0.143 | 0.350 |  < 0.001 |